@petrogustavo Petro es un mal perdedor, un mentiroso y un irresponsable.
El preconteo habla de una diferencia cercana al 1% con el 99,58% de las mesas informadas.
Afortunadamente el 7 de agosto se acaba la horrible noche.
Mientras la gente se muere, el gobierno nombra como superintendente de salud a Daniel Quintero, que tiene 43 miembros de su alcaldía imputados. Es un insulto a los colombianos.
Spotlight: Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk Factors by Alessandro Larcher et al
#Spotlight#Medtwitter#UroSoMe#RenalCancer
At 23 years of follow-up, population-based PSA screening of asymptomatic men led to a sustained reduction in prostate cancer mortality, although overdiagnosis remains a concern. Full ERSPC study results: https://t.co/iwULrhSglD
Editorial: Early Detection of Prostate Cancer — Time to Fish or Cut Bait https://t.co/G9Kmvrqrzj
🚨 New in European Urology:
Consolidative surgery after #EnfortumabVedotin +/– ICI in advanced urothelial carcinoma:
✅ 82% downstaging
✅ 43% ypT0N0
✅ 79% stopped systemic therapy
✅ 89% DFS in curative group
📄 https://t.co/Yd52YZKRNk
#BladderCancer#Immunotherapy#Urology
Intravesical antibody drug Conjugates for #BladderCancer. @DiMariaJiang@pmcancercentre sits down with @UroDocAsh@MDAndersonNews to discuss how ADCs are transforming bladder cancer care and reshaping 1L treatment, boosting neoadjuvant response rates & even sparking bladder preservation conversations. A "golden era" in progress! #WatchNow > https://t.co/QfLzH8Hgl5 💥
New data on hydro TMT in MIBC 🚨guess that’s why it’s not ideal 👎
📊 74% of patients with pre-existing hydronephrosis still had it post-TMT
💧 21% of patients WITHOUT hydronephrosis developed it after TMT
🧵 52% of new cases needed PCNT drainage…. https://t.co/0URFvayrCQ
#BladderCancer
Viewpoint: Prostate cancer screening is shifting toward a more beneficial and less harmful approach by using MRI-targeted strategies, which reduce unnecessary biopsies and overdiagnosis. https://t.co/FsfSs3xmkG @IvoSchootsNL
⚡️ Longitudinal Tumor-informed Circulating Tumor DNA Status Predicts Disease Upstaging and Poor Prognosis for Patients Undergoing Radical Cystectomy - Beyond the Abstract
#BladderCancer@urotoday
https://t.co/k8ZRW3TTAe
PSA dynamics from the phase 3 #EMBARK trial: A post hoc analysis. Presentation by Paul Sieber, MD. #SESAUA25 written coverage by @zklaassen_md > https://t.co/aDVmMKeu3H @SES_AUA
The urology workforce shortage is real. It affects access to care everywhere, particularly in rural areas. We need to continue to adapt and implement strategies to retain and grow #urology@AmerUrological@urogoldjournal
In our latest “Science in Seconds” Dr. @BradMcG04 discusses 2 abstracts findings from phase 3 TALAPRO-2 trial highlighting final OS w TALA + ENZA as 1st-line Tx: 1 for unselected pts w #mCRPC & 1 for pts w HRR-deficient mCRPC. #GU25 https://t.co/YDlKrx7jNv https://t.co/YrXDgjyhx4